
Cardiac ultrasound is a safe and inexpensive test for monitoring and preventing heart disease. Manual work (e.g. measuring, writing report) takes 50-85% of test time. We make cardiac ultrasound more accessible, cheaper and less human reliant by automating the analysis.

Cardiac ultrasound is a safe and inexpensive test for monitoring and preventing heart disease. Manual work (e.g. measuring, writing report) takes 50-85% of test time. We make cardiac ultrasound more accessible, cheaper and less human reliant by automating the analysis.
Product: Ligence Heart — web-based AI software for automated echocardiography analysis and reporting
Regulatory status: FDA 510(k) cleared and CE‑marked
Headquarters: Vilnius, Lithuania
Recent funding: €3M seed round led by Simpact Ventures (Nov 2024)
Team size: ~29 employees
Automating and streamlining echocardiography analysis and reporting to reduce manual workload in cardiac ultrasound.
Software Development
€3M
Includes a convertible loan from the European Innovation Council (EIC) Fund
“Led by Simpact Ventures with participation from the European Innovation Council (convertible loan) and other investors listed on Crunchbase”
| Company |
|---|